Literature DB >> 7342286

Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function.

R C Moellering, D J Krogstad, D J Greenblatt.   

Abstract

Recent novel clinical applications of vancomycin have stimulated reinvestigations of the pharmacologic properties of this drug. Absorption from the gastrointestinal tract is negligible, and oral administration is appropriate only for patients with certain staphylococcal and clostridial diarrheas. After intravenous administration (the intramuscular route being painful), vancomycin is excreted by glomerular filtration, with virtually total recovery in the urine. Distribution is consistent with a three-compartment open pharmacokinetic model. Serum half-life values are usually greater than 8 min in the distribution phase, 30 min to 1.5 hr in the intermediate phase, and between 5 and 11 hr in the elimination phase. The level of binding to human serum proteins is 55%. Since the relation between the vancomycin clearance and the creatinine clearance (but not the level of creatinine in serum) is linear in both normal and impaired renal function, a nomogram has been prepared that delineates dosages that will produce a mean steady-state concentration in serum of 15 micrograms/ml. Vancomycin penetrates well into pericardial, pleural, synovial, and ascitic fluid in humans, but concentrations in cerebrospinal fluid after parenteral administration may be insufficient for the successful treatment of certain cases of meningitis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7342286

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  16 in total

1.  Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.

Authors:  Eugenia Yeh; Glen Brown
Journal:  Can J Hosp Pharm       Date:  2009-11

2.  Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

Authors:  F Marra; B Cairns; P Jewesson
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

3.  Optimal vancomycin doses for methicillin-resistant Staphylococcus aureus infection in urological renal dysfunction patients.

Authors:  Katsumi Shigemura; Kayo Osawa; Fukashi Yamamichi; Kazushi Tanaka; Issei Tokimatsu; Soichi Arakawa; Masato Fujisawa
Journal:  Int Urol Nephrol       Date:  2015-04-22       Impact factor: 2.370

Review 4.  Does oral vancomycin use necessitate therapeutic drug monitoring?

Authors:  Nevio Cimolai
Journal:  Infection       Date:  2019-11-11       Impact factor: 3.553

5.  Vancomycin: renewed interest in an old drug.

Authors:  B B Farber
Journal:  Eur J Clin Microbiol       Date:  1984-02       Impact factor: 3.267

Review 6.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

7.  Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.

Authors:  Megan E DelDot; Jeffrey Lipman; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

8.  Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.

Authors:  I R Friedland; M Paris; S Ehrett; S Hickey; K Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

9.  Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.

Authors:  M M París; S M Hickey; M I Uscher; S Shelton; K D Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

10.  Vancomycin pharmacokinetics in patients with various degrees of renal function.

Authors:  K A Rodvold; R A Blum; J H Fischer; H Z Zokufa; J C Rotschafer; K B Crossley; L J Riff
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.